Fecal immunochemical test screening may impact colorectal cancer surgery rates
the ONA take:
Screening based on fecal immunochemical testing (FIT) may have an impact on both proximal and distal colorectal cancer (CRC) surgery rates, according to an Italian study published online ahead of print inCancer.
Researchers led by Ugo Fedeli, MD, of the Regional Epidemiological Department categorized patients with CRC in the Veneto region of Italy based on staggered introduction of FIT-based screening programs: early (2002 to 2004), intermediate (2005 to 2007), and late (2008 to 2009).
Proximal and distal CRC surgery rates were investigated in these three populations between 2001 and 2012 through Joinpoint regression analysis and segmented Poisson regression models.
The researchers found that impact of screening was similar in study populations. Distal CRC surgical resection rates were found to be stable before screening, increased at time of screening implementation, and declined afterward by 10 percent annually.
Proximal CRC surgical resection rates increased by four percent annually before screening, but after a peak with screening initiation had reversed thereafter. In addition, the percentage represented by proximal CRC surgery rose from 28 percent in 2001 to 41 percent in 2012.They concluded that their “findings across each time series demonstrated that FIT-based screening programs have an impact on proximal and distal CRC surgery rates. “ However, they also noted that “underlying preexisting epidemiological trends are leading to a rapidly increasing percentage of proximal CRC.”
Screening based on fecal immunochemical testing (FIT) may have an impact on both proximal and distal colorectal cancer (CRC) surgery rates.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|